Summarizing historical information on controls in clinical trials

样本量测定 临床试验 统计 样品(材料) 随机对照试验 计算机科学 计量经济学 医学 数学 内科学 化学 色谱法
作者
Beat Neuenschwander,Gorana Capkun-Niggli,Michael Branson,David J. Spiegelhalter
出处
期刊:Clinical Trials [SAGE Publishing]
卷期号:7 (1): 5-18 被引量:294
标识
DOI:10.1177/1740774509356002
摘要

Historical information is always relevant when designing clinical trials, but it might also be incorporated in the analysis. It seems appropriate to exploit past information on comparable control groups.Phase IV and proof-of-concept trials are used to discuss aspects of summarizing historical control data as prior information in a new trial. The importance of a fair assessment of the similarity of control parameters is emphasized.The methodology is meta-analytic-predictive. Heterogeneity of control parameters is expressed via the between-trial variation, which is the key parameter determining the prior effective sample size and its upper bound (prior maximum sample size).For a Phase IV trial (930 control patients in 11 historical trials) between-trial heterogeneity was fairly small, resulting in a prior effective sample size of approximately 90 patients. For a proof-of-concept trial (363 patients in four historical trials) heterogeneity was moderate to substantial, resulting in a prior effective sample size of approximately 20. For another proof-of-concept trial (14 patients in one historical trial), assuming substantial heterogeneity implied a prior effective sample size of 7. The prior effective sample size can only be large if the amount of historical data is large and between-trial heterogeneity is small. The prior effective sample size is bounded by the prior maximum sample size (ratio of within- to between-trial variance), irrespective of the amount of historical data.The meta-analytic-predictive approach assumes exchangeability of control parameters across trials. Due to the difficulty to quantify between-trial variability, sensitivity of conclusions regarding assumptions and type of inference should be assessed.The use of historical control information is a valuable option and may lead to more efficient clinical trials. The proposed approach is attractive for nonconfirmatory trials, but under certain circumstances extensions to the confirmatory setting could be envisaged as well.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Yao完成签到 ,获得积分10
刚刚
烟花的应助被少锋x采纳,获得10
刚刚
ihyomong完成签到,获得积分10
1秒前
1秒前
Cher.发布了新的文献求助10
1秒前
嗯哦完成签到,获得积分10
1秒前
2秒前
2秒前
3秒前
zzz完成签到,获得积分10
4秒前
反杀闰土的猹完成签到,获得积分10
4秒前
4秒前
秋风的应助被李旭东采纳,获得30
5秒前
5秒前
5秒前
6秒前
今后的应助被ihyomong采纳,获得10
7秒前
8秒前
8秒前
小七发布了新的文献求助10
8秒前
Sledge的应助被科研通管家采纳,获得10
8秒前
8秒前
乐乐的应助被科研通管家采纳,获得10
8秒前
9秒前
9秒前
深情安青的应助被科研通管家采纳,获得10
9秒前
成就灭龙的应助被科研通管家采纳,获得10
9秒前
9秒前
Hello的应助被科研通管家采纳,获得10
9秒前
一笑没的应助被科研通管家采纳,获得10
9秒前
桐桐的应助被科研通管家采纳,获得10
10秒前
molihuakai的应助被科研通管家采纳,获得10
10秒前
10秒前
wxm的应助被科研通管家采纳,获得10
10秒前
成就灭龙的应助被科研通管家采纳,获得10
10秒前
10秒前
一笑没的应助被科研通管家采纳,获得10
10秒前
wuwu的应助被科研通管家采纳,获得10
10秒前
酷波er的应助被科研通管家采纳,获得10
11秒前
xuyang完成签到,获得积分10
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Encyclopedia of Modern Artificial Intelligence 1000
Особенности технологий и методов информационно-психологических войн СССР с Великобританией и США в период 1939-1953 гг 1000
Das Matthäusevangelium: Kapitel 1:1–17 1000
IRTSD: Open-Source Data and Toolset for Electromagnetic Transient Analysis of Disturbances and IBR Control Malfunctions in Transmission Systems 1000
Entre Praga y Madrid : los contactos checoslovaco-españoles (1948-1977) 600
Les Mots du discours 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8134117
求助须知:如何正确求助?哪些是违规求助? 9535666
关于积分的说明 21613861
捐赠科研通 7716699
什么是DOI,文献DOI怎么找? 3419134
关于科研通互助平台的介绍 2544507
邀请新用户注册赠送积分活动 2460637